Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | LAP3 | P28838 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413973 | 0.76 | FDPS (0.56) | MMP8MMP1MMP2FDPSLAP3 | |
| SCHEMBL6438981 | 0.74 | FDPS (0.38) | MMP8MMP1MMP2FDPSLAP3 | |
| SCHEMBL4103874 | 0.72 | GNAI3 (0.32) | GNAI3GNAO1GNAI1 | |
| SCHEMBL7450835 | 0.71 | FDPS (0.35) | FDPSLAP3 | |
| SCHEMBL27567759 | 0.71 | GNAI3 (0.36) | MMP8MMP1MMP2GNAI3GNAO1 | |
| SCHEMBL222544 | 0.71 | CHRNA7 (0.34) | GNAI3GNAO1GNAI1 | |
| SCHEMBL11331122 | 0.69 | ANPEP (0.43) | MMP8MMP1FDPS | |
| SCHEMBL6419834 | 0.69 | ITGB3 (0.36) | GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL1456033 | 0.69 | GNAI3 (0.38) | GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL222616 | 0.69 | GNAI3 (0.38) | GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | MMP8 3983/4885MMP1 4600/4885MMP2 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.